• 20+ years of consecutive growth - now 674 Chemist Warehouse (CW) stores globally
• Execution of margin enhancing own and exclusive label strategy
• Synergies target upgraded to $100m per annum by year four

Sigma Healthcare Ltd reported its FY25 results, highlighting strong execution of its growth strategy. The company achieved 20+ years of consecutive growth, with 674 Chemist Warehouse (CW) stores globally. CW franchise stores in Australia saw 11.3% like-for-like sales growth, and the CW retail network sales reached $10.3bn, up 14% for the year. Sigma also executed its margin-enhancing own and exclusive label strategy, launching the Wagner generic medicines brand in November 2024 and achieving over 20% growth in FY25 sales of own and exclusive label products. The company delivered efficiencies and synergies, upgrading its synergies target to $100m per annum by year four, with distribution centre volumes up 29% to over 532m units and logistics costs down 11% per unit. Financially, Sigma reported Normalised revenue up 82.3% to $6.0bn, Normalised EBIT up 41.4% to $834.5m, and Pro-forma EBIT of $903.4m. The company maintained a conservative balance sheet with net debt to Normalised EBITDA of 0.85x and secured a $1.5bn debt facility to provide funding flexibility. Sigma is focused on executing its key strategic growth pillars of domestic growth, international expansion, product strategy, and efficiencies and synergies.

Sigma reported Pro-forma revenue of $9.6bn and Pro-forma EBIT of $903.4m for FY25, reflecting the full 12-month impact of the Sigma and CWG merger.

Sigma is confident in its ability to execute with excellence, with a strong start to FY26 expected, including double-digit like-for-like CW retail network sales growth, as the company's value proposition continues to resonate with retail customers across markets.